Compare Citius Pharmaceuticals Inc (CTXR) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Johnson Controls International PLC — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Johnson Controls International PLC trades at $158.04 (market cap $93.28B). The key difference: Johnson Controls International PLC is far larger — about 6848.8× Citius Pharmaceuticals Inc's market cap, and Johnson Controls International PLC pays a 1.04% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Johnson Controls International PLC for 65 Days on average.
| CTXR | JCI | |
|---|---|---|
Market Cap | $13.62M | $93.28B |
Volume | 132,438 | 2,786,476 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $158.76 |
52-Week Low | $0.48 | $105.55 |
Typical Hold Time | 17 Days | 65 Days |
Enterprise Value | $3.79M | $102.12B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Johnson Controls International (JCI) trades at $157.46, up 0.98% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $1.42 versus $1.30 expected, and revenue growth accelerating to 9% in Q3 2026. Valuation metrics remain elevated with P/E at 43.38, but profitability is strong with net income margin of 14.32% and ROE of 24.42%.
JCI presents a favorable investment case with consistent earnings beats, raised FY26 guidance, and strong institutional support. Key risks include high valuation multiples and increasing debt-to-asset ratio reaching 26.06% in 2025. The consensus price target of $172.50 suggests 9.6% upside potential from current levels, supported by 28 buy ratings and no sell recommendations from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
